þ | Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
o | Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
Delaware | 33-0804655 | |
(State or other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.) | |
9885 Towne Centre Drive, San Diego, CA | 92121 | |
(Address of Principal Executive Offices) | (Zip Code) |
Large accelerated filer þ
|
Accelerated filer o | Non-accelerated filer o | Smaller reporting company o | |||
(Do not check if a smaller reporting company) |
Page | ||||||||
3 | ||||||||
3 | ||||||||
4 | ||||||||
5 | ||||||||
6 | ||||||||
18 | ||||||||
26 | ||||||||
27 | ||||||||
27 | ||||||||
27 | ||||||||
27 | ||||||||
28 | ||||||||
28 | ||||||||
28 | ||||||||
29 | ||||||||
30 | ||||||||
EX-31.1 | ||||||||
EX-31.2 | ||||||||
EX-32.1 | ||||||||
EX-32.2 | ||||||||
EX-101 INSTANCE DOCUMENT | ||||||||
EX-101 SCHEMA DOCUMENT | ||||||||
EX-101 CALCULATION LINKBASE DOCUMENT | ||||||||
EX-101 LABELS LINKBASE DOCUMENT | ||||||||
EX-101 PRESENTATION LINKBASE DOCUMENT | ||||||||
EX-101 DEFINITION LINKBASE DOCUMENT |
2
July 3, | January 2, | |||||||
2011 | 2011 | |||||||
(Unaudited) | ||||||||
ASSETS |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ | 261,084 | $ | 248,947 | ||||
Short-term investments |
972,830 | 645,342 | ||||||
Accounts receivable, net |
193,431 | 165,598 | ||||||
Inventory, net |
142,583 | 142,211 | ||||||
Deferred tax assets, current portion |
22,450 | 19,378 | ||||||
Prepaid expenses and other current assets |
30,937 | 36,922 | ||||||
Total current assets |
1,623,315 | 1,258,398 | ||||||
Property and equipment, net |
129,762 | 129,874 | ||||||
Goodwill |
321,853 | 278,206 | ||||||
Intangible assets, net |
112,708 | 91,462 | ||||||
Deferred tax assets, long-term portion |
16,990 | 39,497 | ||||||
Other assets |
52,358 | 41,676 | ||||||
Total assets |
$ | 2,256,986 | $ | 1,839,113 | ||||
LIABILITIES AND STOCKHOLDERS EQUITY |
||||||||
Current liabilities: |
||||||||
Accounts payable |
$ | 58,270 | $ | 66,744 | ||||
Accrued liabilities |
185,536 | 156,164 | ||||||
Long-term debt, current portion |
40,649 | 311,609 | ||||||
Total current liabilities |
284,455 | 534,517 | ||||||
Long-term debt |
757,274 | | ||||||
Other long-term liabilities |
38,512 | 28,531 | ||||||
Conversion option subject to cash settlement |
8,441 | 78,390 | ||||||
Stockholders equity: |
||||||||
Preferred stock |
| | ||||||
Common stock |
1,651 | 1,516 | ||||||
Additional paid-in capital |
2,170,564 | 1,891,288 | ||||||
Accumulated other comprehensive income |
2,347 | 1,765 | ||||||
Accumulated deficit |
(100,584 | ) | (155,335 | ) | ||||
Treasury stock, at cost |
(905,674 | ) | (541,559 | ) | ||||
Total stockholders equity |
1,168,304 | 1,197,675 | ||||||
Total liabilities and stockholders equity |
$ | 2,256,986 | $ | 1,839,113 | ||||
3
Three Months Ended | Six Months Ended | |||||||||||||||
July 3, | July 4, | July 3, | July 4, | |||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
Revenue: |
||||||||||||||||
Product revenue |
$ | 269,871 | $ | 198,538 | $ | 536,588 | $ | 372,217 | ||||||||
Service and other revenue |
17,579 | 13,465 | 33,377 | 31,917 | ||||||||||||
Total revenue |
287,450 | 212,003 | 569,965 | 404,134 | ||||||||||||
Cost of revenue: |
||||||||||||||||
Cost of product revenue |
84,518 | 59,627 | 169,955 | 112,566 | ||||||||||||
Cost of service and other revenue |
6,541 | 4,690 | 12,593 | 10,084 | ||||||||||||
Amortization of acquired intangible assets |
3,035 | 1,595 | 6,020 | 3,215 | ||||||||||||
Total cost of revenue |
94,094 | 65,912 | 188,568 | 125,865 | ||||||||||||
Gross profit |
193,356 | 146,091 | 381,397 | 278,269 | ||||||||||||
Operating expense: |
||||||||||||||||
Research and development |
50,801 | 43,667 | 101,001 | 87,343 | ||||||||||||
Selling, general and administrative |
69,233 | 53,135 | 134,894 | 103,414 | ||||||||||||
Acquisition related expense, net |
4,770 | 1,861 | 5,040 | 1,861 | ||||||||||||
Headquarter relocation expense |
2,542 | | 5,064 | | ||||||||||||
Total operating expense |
127,346 | 98,663 | 245,999 | 192,618 | ||||||||||||
Income from operations |
66,010 | 47,428 | 135,398 | 85,651 | ||||||||||||
Other income (expense): |
||||||||||||||||
Interest income |
1,981 | 1,751 | 3,521 | 3,955 | ||||||||||||
Interest expense |
(9,418 | ) | (6,134 | ) | (16,809 | ) | (12,089 | ) | ||||||||
Other (expense) income, net |
(9,549 | ) | 3,481 | (37,078 | ) | 2,369 | ||||||||||
Total other expense, net |
(16,986 | ) | (902 | ) | (50,366 | ) | (5,765 | ) | ||||||||
Income before income taxes |
49,024 | 46,526 | 85,032 | 79,886 | ||||||||||||
Provision for income taxes |
18,404 | 16,730 | 30,275 | 28,882 | ||||||||||||
Net income |
$ | 30,620 | $ | 29,796 | $ | 54,757 | $ | 51,004 | ||||||||
Net income per basic share |
$ | 0.25 | $ | 0.24 | $ | 0.44 | $ | 0.42 | ||||||||
Net income per diluted share |
$ | 0.22 | $ | 0.21 | $ | 0.37 | $ | 0.37 | ||||||||
Shares used in calculating basic net income per share |
123,456 | 123,095 | 124,987 | 121,882 | ||||||||||||
Shares used in calculating diluted net income per share |
141,765 | 140,951 | 147,447 | 138,682 | ||||||||||||
4
Six Months Ended | ||||||||
July 3, | July 4, | |||||||
2011 | 2010 | |||||||
Cash flows from operating activities: |
||||||||
Net income |
$ | 54,757 | $ | 51,004 | ||||
Adjustments to reconcile net income to net cash provided by operating activities: |
||||||||
Depreciation expense |
25,989 | 15,804 | ||||||
Amortization of acquired intangible assets |
6,313 | 3,215 | ||||||
Share-based compensation expense |
45,705 | 33,844 | ||||||
Accretion of debt discount |
15,185 | 10,504 | ||||||
Loss on extinguishment of debt |
36,856 | | ||||||
Contingent compensation expense |
2,573 | 1,838 | ||||||
Gain on acquisition |
| (2,914 | ) | |||||
Incremental tax benefit related to stock options exercised |
(33,320 | ) | (8,000 | ) | ||||
Deferred income taxes |
4,121 | 8,040 | ||||||
Other non-cash adjustments |
4,837 | 1,436 | ||||||
Changes in operating assets and liabilities: |
||||||||
Accounts receivable |
(20,751 | ) | 6,162 | |||||
Inventory |
4,524 | (27,766 | ) | |||||
Prepaid expenses and other current assets |
(6,539 | ) | 2,092 | |||||
Other assets |
(3,632 | ) | (1,460 | ) | ||||
Accounts payable |
(9,969 | ) | 16,383 | |||||
Accrued liabilities |
30,671 | 22,398 | ||||||
Other long-term liabilities |
1,248 | (799 | ) | |||||
Unrealized gain on foreign exchange |
1,230 | 4,483 | ||||||
Net cash provided by operating activities |
159,798 | 136,264 | ||||||
Cash flows from investing activities: |
||||||||
Purchases of available-for-sale securities |
(806,985 | ) | (313,017 | ) | ||||
Sales and maturities of available-for-sale securities |
476,460 | 256,034 | ||||||
Sales and maturities of trading securities |
| 54,900 | ||||||
Net cash paid for acquisitions |
(58,302 | ) | (75,069 | ) | ||||
Purchases of investments |
(6,708 | ) | (17,650 | ) | ||||
Purchases of property and equipment |
(28,503 | ) | (24,322 | ) | ||||
Cash paid for intangible assets |
(1,102 | ) | (2,000 | ) | ||||
Net cash used in investing activities |
(425,140 | ) | (121,124 | ) | ||||
Cash flows from financing activities: |
||||||||
Payments on current portion of long-term debt |
(340,909 | ) | | |||||
Proceeds from issuance of convertible notes |
903,492 | | ||||||
Incremental tax benefit related to stock options exercised |
33,320 | 8,000 | ||||||
Common stock repurchases |
(366,326 | ) | | |||||
Proceeds from exercises of warrants |
5,512 | 9,587 | ||||||
Proceeds from issuance of common stock |
41,909 | 59,935 | ||||||
Net cash provided by financing activities |
276,998 | 77,522 | ||||||
Effect of exchange rate changes on cash and cash equivalents |
481 | (108 | ) | |||||
Net increase in cash and cash equivalents |
12,137 | 92,554 | ||||||
Cash and cash equivalents at beginning of period |
248,947 | 144,633 | ||||||
Cash and cash equivalents at end of period |
$ | 261,084 | $ | 237,187 | ||||
5
6
7
| Level 1 Quoted prices in active markets for identical assets or liabilities. |
| Level 2 Inputs, other than Level 1, that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. |
| Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. |
8
Three Months Ended | Six Months Ended | |||||||||||||||
July 3, | July 4, | July 3, | July 4, | |||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
Weighted average shares outstanding |
123,456 | 123,095 | 124,987 | 121,882 | ||||||||||||
Effect of dilutive potential common shares: |
||||||||||||||||
Dilutive convertible senior notes |
2,408 | 8,404 | 6,681 | 7,926 | ||||||||||||
Dilutive equity awards |
5,607 | 4,295 | 5,698 | 4,244 | ||||||||||||
Dilutive warrants sold in connection with convertible senior notes |
10,294 | 4,351 | 10,081 | 3,645 | ||||||||||||
Dilutive warrants assumed in an acquisition |
| 806 | | 985 | ||||||||||||
Weighted average shares used in calculation of diluted net income per share |
141,765 | 140,951 | 147,447 | 138,682 | ||||||||||||
Weighted average shares excluded from calculation due to anti-dilutive effect |
1,194 | 1,480 | 1,012 | 1,325 | ||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
July 3, | July 4, | July 3, | July 4, | |||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
Net income |
$ | 30,620 | $ | 29,796 | $ | 54,757 | $ | 51,004 | ||||||||
Unrealized gain (loss) on available-for-sale securities, net of deferred tax |
1,227 | (39 | ) | 582 | (217 | ) | ||||||||||
Total comprehensive income |
$ | 31,847 | $ | 29,757 | $ | 55,339 | $ | 50,787 | ||||||||
9
July 3, 2011 | ||||||||||||||||
Gross | Gross | |||||||||||||||
Amortized | Unrealized | Unrealized | Estimated | |||||||||||||
Cost | Gains | Losses | Fair Value | |||||||||||||
Available-for-sale securities: |
||||||||||||||||
Debt securities in government sponsored entities |
$ | 437,406 | $ | 480 | $ | (166 | ) | $ | 437,720 | |||||||
Corporate debt securities |
484,715 | 1,400 | (251 | ) | 485,864 | |||||||||||
U.S. Treasury securities |
49,076 | 176 | (6 | ) | 49,246 | |||||||||||
Total available-for-sale securities |
$ | 971,197 | $ | 2,056 | $ | (423 | ) | $ | 972,830 | |||||||
January 2, 2011 | ||||||||||||||||
Gross | Gross | |||||||||||||||
Amortized | Unrealized | Unrealized | Estimated | |||||||||||||
Cost | Gains | Losses | Fair Value | |||||||||||||
Available-for-sale securities: |
||||||||||||||||
Debt securities in government sponsored entities |
$ | 261,890 | $ | 106 | $ | (299 | ) | $ | 261,697 | |||||||
Corporate debt securities |
329,823 | 1,170 | (235 | ) | 330,758 | |||||||||||
U.S. Treasury securities |
52,938 | 70 | (121 | ) | 52,887 | |||||||||||
Total available-for-sale securities |
$ | 644,651 | $ | 1,346 | $ | (655 | ) | $ | 645,342 | |||||||
July 3, 2011 | January 2, 2011 | |||||||||||||||
Gross | Gross | |||||||||||||||
Unrealized | Unrealized | |||||||||||||||
Fair Value | Losses | Fair Value | Losses | |||||||||||||
Debt securities in government sponsored entities |
$ | 144,770 | $ | (166 | ) | $ | 127,756 | $ | (299 | ) | ||||||
Corporate debt securities |
141,622 | (251 | ) | 92,199 | (235 | ) | ||||||||||
U.S. Treasury securities |
1,796 | (6 | ) | 13,490 | (121 | ) | ||||||||||
Total |
$ | 288,188 | $ | (423 | ) | $ | 233,445 | $ | (655 | ) | ||||||
10
Estimated | ||||
Fair Value | ||||
Due within one year |
$ | 276,347 | ||
After one but within five years |
696,483 | |||
Total |
$ | 972,830 | ||
July 3, | January 2, | |||||||
2011 | 2011 | |||||||
Raw materials |
$ | 62,031 | $ | 54,762 | ||||
Work in process |
60,542 | 64,862 | ||||||
Finished goods |
20,010 | 22,587 | ||||||
Total inventory, net |
$ | 142,583 | $ | 142,211 | ||||
July 3, | January 2, | |||||||
2011 | 2011 | |||||||
Deferred revenue, current portion |
$ | 52,833 | $ | 45,863 | ||||
Accrued compensation expenses |
43,581 | 49,368 | ||||||
Accrued taxes payable |
34,677 | 13,277 | ||||||
Reserve for product warranties |
16,911 | 16,761 | ||||||
Customer deposits |
14,574 | 14,900 | ||||||
Acquisition related contingent consideration liability, current portion |
6,092 | 3,738 | ||||||
Accrued royalties |
4,276 | 2,781 | ||||||
Other accrued expenses |
12,592 | 9,476 | ||||||
Total accrued liabilities |
$ | 185,536 | $ | 156,164 | ||||
11
Three Months Ended | Six Months Ended | |||||||||||||||
July 3, | July 4, | July 3, | July 4, | |||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
Contingent compensation expense, included in research and development expense |
$ | 1,855 | $ | 919 | $ | 3,292 | $ | 1,838 | ||||||||
Contingent compensation expense, included in selling, general and administrative
expense |
851 | | 1,538 | | ||||||||||||
Total contingent compensation expense |
$ | 2,706 | $ | 919 | $ | 4,830 | $ | 1,838 | ||||||||
IPR&D, included in acquisition related expense, net |
$ | 5,425 | $ | 1,325 | $ | 5,425 | $ | 1,325 | ||||||||
12
July 3, 2011 | ||||||||||||||||
Quoted Prices in | ||||||||||||||||
Active Markets for | Significant Other | Significant | ||||||||||||||
Identical Assets | Observable Inputs | Unobservable | ||||||||||||||
(Level 1) | (Level 2) | Inputs (Level 3) | Total | |||||||||||||
Assets: |
||||||||||||||||
Money market funds (cash equivalent) |
$ | 172,360 | $ | | $ | | $ | 172,360 | ||||||||
Debt securities in government sponsored entities |
| 437,720 | | 437,720 | ||||||||||||
Corporate debt securities |
| 485,864 | | 485,864 | ||||||||||||
U.S. Treasury securities |
49,246 | | | 49,246 | ||||||||||||
Total assets measured at fair value |
$ | 221,606 | $ | 923,584 | $ | | $ | 1,145,190 | ||||||||
Liability: |
||||||||||||||||
Contingent consideration |
$ | | $ | | $ | 10,760 | $ | 10,760 | ||||||||
January 2, 2011 | ||||||||||||||||
Quoted Prices in | ||||||||||||||||
Active Markets for | Significant Other | Significant | ||||||||||||||
Identical Assets | Observable Inputs | Unobservable | ||||||||||||||
(Level 1) | (Level 2) | Inputs (Level 3) | Total | |||||||||||||
Assets: |
||||||||||||||||
Money market funds (cash equivalent) |
$ | 148,822 | $ | | $ | | $ | 148,822 | ||||||||
Debt securities in government sponsored entities |
| 261,697 | | 261,697 | ||||||||||||
Corporate debt securities |
| 330,758 | | 330,758 | ||||||||||||
U.S. Treasury securities |
52,887 | | | 52,887 | ||||||||||||
Total assets measured at fair value |
$ | 201,709 | $ | 592,455 | $ | | $ | 794,164 | ||||||||
Liability: |
||||||||||||||||
Contingent consideration |
$ | | $ | | $ | 3,738 | $ | 3,738 | ||||||||
Contingent | ||||
Consideration | ||||
Liability | ||||
(Level 3 Measurement) | ||||
Balance at January 2, 2011 |
$ | 3,738 | ||
Acquisition of Epicentre |
7,400 | |||
Gain recorded in acquisition related expense, net |
(378 | ) | ||
Balance at July 3, 2011 |
$ | 10,760 | ||
Balance as of January 2, 2011 |
$ | 16,761 | ||
Additions charged to cost of revenue |
14,110 | |||
Repairs and replacements |
(13,960 | ) | ||
Balance as of July 3, 2011 |
$ | 16,911 | ||
13
14
Three Months Ended | Six Months Ended | |||||||
Cash paid for principal of notes converted |
$ | 87,774 | $ | 340,909 | ||||
Conversion value over principal amount paid in shares of common stock |
$ | 194,902 | $ | 716,433 | ||||
Number of shares of common stock issued upon conversion |
2,739 | 10,488 | ||||||
Loss on extinguishment of debt |
$ | 9,680 | $ | 36,856 | ||||
Effective interest rates used to measure fair value of converted notes |
3.6% - 3.9 | % | 3.6% - 4.0 | % |
July 3, 2011 | ||||||||
0.25% Convertible | 0.625% Convertible | |||||||
Senior Notes due 2016 | Senior Notes due 2014 | |||||||
Principal amount of convertible notes outstanding |
$ | 920,000 | $ | 49,090 | ||||
Unamortized discount of liability component |
(162,726 | ) | (8,441 | ) | ||||
Net carrying amount of liability component |
757,274 | 40,649 | ||||||
Less: current portion |
| (40,649 | ) | |||||
Long-term debt |
$ | 757,274 | $ | | ||||
Conversion option subject to cash settlement |
| $ | 8,441 | |||||
Carrying value of equity component, net of debt issuance cost |
$ | 155,366 | $ | 112,039 | ||||
Fair value of outstanding notes |
$ | 997,239 | $ | 172,722 | ||||
Remaining amortization period of discount on the liability component |
4.7 years | 2.6 years |
January 2, 2011 | ||||
0.625% Convertible | ||||
Senior Notes due 2014 | ||||
Principal amount of convertible notes outstanding |
$ | 389,999 | ||
Unamortized discount of liability component |
(78,390 | ) | ||
Net carrying amount of liability component, current |
$ | 311,609 | ||
Conversion option subject to cash settlement |
$ | 78,390 | ||
Carrying value of equity component, net of debt issuance cost |
$ | 71,199 | ||
Fair value of outstanding notes |
$ | 1,157,450 | ||
Remaining amortization period of discount on the liability component |
3.1 years |
15
Three Months Ended | Six Months Ended | |||||||||||||||
July 3, | July 4, | July 3, | July 4, | |||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
Cost of product revenue |
$ | 1,800 | $ | 1,301 | $ | 3,312 | $ | 2,510 | ||||||||
Cost of service and other revenue |
132 | 146 | 342 | 257 | ||||||||||||
Research and development |
8,461 | 6,032 | 16,188 | 11,930 | ||||||||||||
Selling, general and administrative |
13,273 | 9,366 | 25,863 | 19,147 | ||||||||||||
Share-based compensation expense before taxes |
23,666 | 16,845 | 45,705 | 33,844 | ||||||||||||
Related income tax benefits |
(8,199 | ) | (5,586 | ) | (15,960 | ) | (11,532 | ) | ||||||||
Share-based compensation expense, net of taxes |
$ | 15,467 | $ | 11,259 | $ | 29,745 | $ | 22,312 | ||||||||
Three Months Ended July 3, 2011 | ||||||||
Employee Stock | Employee Stock | |||||||
Options | Purchase Rights | |||||||
Interest rate |
2.22 | % | 0.18 0.28 | % | ||||
Volatility |
41 | % | 43 46 | % | ||||
Expected life |
5.5 years | 6 12 months | ||||||
Expected dividend yield |
0 | % | 0 | % | ||||
Weighted average fair value per share |
$ | 31.23 | $18.60 |
Weighted | ||||||||||||
Weighted | Average | |||||||||||
Average | Grant-Date | |||||||||||
Exercise Price | Fair Value | |||||||||||
Options | per Share | per Share | ||||||||||
(in thousands) | ||||||||||||
Outstanding at January 2, 2011 |
11,882 | $ | 22.83 | $ | 12.82 | |||||||
Granted |
1,226 | 70.06 | 29.53 | |||||||||
Exercised |
(2,124 | ) | 17.41 | 10.29 | ||||||||
Cancelled |
(34 | ) | 21.17 | 13.36 | ||||||||
Outstanding at July 3, 2011 |
10,950 | $ | 29.17 | $ | 15.18 | |||||||
16
Weighted Average | ||||||||
Restricted | Grant-Date Fair | |||||||
Stock Units(1) | Value per Share | |||||||
(in thousands) | ||||||||
Outstanding at January 2, 2011 |
3,109 | $ | 40.39 | |||||
Awarded |
445 | 69.84 | ||||||
Vested |
(255 | ) | 35.01 | |||||
Cancelled |
(95 | ) | 39.09 | |||||
Outstanding at July 3, 2011 |
3,204 | $ | 44.96 | |||||
(1) | The fair value of each restricted stock unit represents the fair market value of one share of the Companys common stock. |
17
| Business Overview and Outlook. High level discussion of our operating results and significant known trends that affect our business. | ||
| Results of Operations. Detailed discussion of our revenues and expenses. | ||
| Liquidity and Capital Resources. Discussion of key aspects of our statements of cash flows, changes in our financial position, and our financial commitments. | ||
| Off-Balance Sheet Arrangements. We have no significant off-balance sheet arrangements. | ||
| Critical Accounting Policies and Estimates. Discussion of significant changes since our most recent Annual Report on Form 10-K that we believe are important to understanding the assumptions and judgments underlying our financial statements. | ||
| Recent Accounting Pronouncements. Description of recent accounting pronouncements and the potential impact of these pronouncements on our financial position, results of operations, and cash flows. |
18
19
| Net revenue grew by 41% during the first half of 2011 compared to the first half of 2010. The increase in revenue was primarily driven by increased HiSeq 2000 shipments, an overall improvement in our microarray business, and an increase in consumables sales as our installed base expands. | ||
| Gross profit as a percentage of revenue (gross margin) in the first half of 2011 decreased slightly from the first half of 2010 due to a shift in sales mix from higher gross margin consumables to lower gross margin instruments. The change in mix was primarily due to the launch of the HiSeq 2000, which did not begin volume shipments until the second half of 2010. Lower gross margins on instrument sales reflect the effects of promotional program discounts provided to customers on HiSeq 2000 sales, including the Genome Analyzer trade-in program. Over the remainder of 2011, we believe several factors may contribute to improved gross margin, including an increase in sales of consumables as a percentage of total revenue and the completion of the Genome Analyzer trade-in program. | ||
| Income from operations increased 58% in the first half of 2011 compared to the first half of 2010 primarily due to higher revenue. Total operating expense increased by 28% in the same period. We anticipate our research and development expense to increase in absolute dollars as we continue to expand our product development portfolio. Selling, general and administrative expense is also expected to increase in absolute dollars as we continue to invest in personnel and infrastructure to support revenue growth, global expansion, and penetration of other markets such as the lower throughput sequencing market. | ||
| In December 2010, we entered into a lease agreement for new corporate headquarters. During the first half of 2011, we incurred $5.1 million in headquarter relocation expense. We expect to incur additional headquarter relocation expense during the remainder of 2011, such as a cease-use loss upon vacating our current headquarters, accelerated depreciation of certain property and equipment, and double rent expense during the transition to the new facility. | ||
| Our effective tax rate during the first half of 2011 was 35.6%. The provision for income taxes is dependent on the mix of earnings in tax jurisdictions with different statutory tax rates and the other factors discussed in the risk factor We are subject to risks related to taxation in multiple jurisdictions and the possible loss of the tax deduction on our outstanding convertible notes in Item 1A of our Annual Report on Form 10-K for the fiscal year ended January 2, 2011. For 2011, we anticipate the provision for income taxes to increase in absolute dollars and the effective tax rate to approximate the U.S. federal statutory rate due to a significant portion of our earnings being subject to taxation in the U.S. However, we anticipate the effective tax rate to decrease over time as the proportion of our earnings subject to lower statutory tax rates increases. We anticipate significant income tax payments in 2011 and beyond due to the expected utilization of the majority of our net operating loss carryforwards and U.S. federal research and development tax credit carryforwards. | ||
| We ended the first half of 2011 with cash, cash equivalents, and short-term investments totaling $1.2 billion. In the first half of 2011, we generated $159.8 million in cash from operations, a $23.5 million, or 17%, increase from the first half of 2010. During the same period, we also generated $903.5 million in net proceeds from the issuance of our 0.25% Convertible Senior Notes due 2016, used $366.3 million to repurchase shares of our common stock, and used $340.9 million to repay our existing 0.625% Convertible Senior Notes due 2014. |
20
Q2 2011 | Q2 2010 | YTD 2011 | YTD 2010 | |||||||||||||
Revenue: |
||||||||||||||||
Product revenue |
94 | % | 94 | % | 94 | % | 92 | % | ||||||||
Service and other revenue |
6 | 6 | 6 | 8 | ||||||||||||
Total revenue |
100 | 100 | 100 | 100 | ||||||||||||
Cost of revenue: |
||||||||||||||||
Cost of product revenue |
29 | 28 | 30 | 28 | ||||||||||||
Cost of service and other revenue |
2 | 2 | 2 | 2 | ||||||||||||
Amortization of acquired intangible assets |
1 | 1 | 1 | 1 | ||||||||||||
Total cost of revenue |
32 | 31 | 33 | 31 | ||||||||||||
Gross profit |
68 | 69 | 67 | 69 | ||||||||||||
Operating expense: |
||||||||||||||||
Research and development |
18 | 21 | 18 | 22 | ||||||||||||
Selling, general and administrative |
24 | 25 | 23 | 26 | ||||||||||||
Acquisition related expense, net |
2 | 1 | 1 | | ||||||||||||
Headquarter relocation expense |
1 | | 1 | | ||||||||||||
Total operating expense |
45 | 47 | 43 | 48 | ||||||||||||
Income from operations |
23 | 22 | 24 | 21 | ||||||||||||
Other income (expense): |
||||||||||||||||
Interest income |
1 | 1 | 1 | 1 | ||||||||||||
Interest expense |
(3 | ) | (3 | ) | (3 | ) | (3 | ) | ||||||||
Other (expense) income, net |
(4 | ) | 2 | (7 | ) | 1 | ||||||||||
Total other expense, net |
(6 | ) | | (9 | ) | (1 | ) | |||||||||
Income before income taxes |
17 | 22 | 15 | 20 | ||||||||||||
Provision for income taxes |
6 | 8 | 5 | 7 | ||||||||||||
Net income |
11 | % | 14 | % | 10 | % | 13 | % | ||||||||
Percentage | Percentage | |||||||||||||||||||||||||||||||
(Dollars in thousands) | Q2 2011 | Q2 2010 | Change | Change | YTD 2011 | YTD 2010 | Change | Change | ||||||||||||||||||||||||
Product revenue |
$ | 269,871 | $ | 198,538 | $ | 71,333 | 36 | % | $ | 536,588 | $ | 372,217 | $ | 164,371 | 44 | % | ||||||||||||||||
Service and other revenue |
17,579 | 13,465 | 4,114 | 31 | 33,377 | 31,917 | 1,460 | 5 | ||||||||||||||||||||||||
Total revenue |
$ | 287,450 | $ | 212,003 | $ | 75,447 | 36 | % | $ | 569,965 | $ | 404,134 | $ | 165,831 | 41 | % | ||||||||||||||||
21
Percentage | Percentage | |||||||||||||||||||||||||||||||
(Dollars in thousands) | Q2 2011 | Q2 2010 | Change | Change | YTD 2011 | YTD 2010 | Change | Change | ||||||||||||||||||||||||
Gross profit |
$ | 193,356 | $ | 146,091 | $ | 47,265 | 32 | % | $ | 381,397 | $ | 278,269 | $ | 103,128 | 37 | % | ||||||||||||||||
Gross margin |
67.3 | % | 68.9 | % | 66.9 | % | 68.9 | % |
Percentage | Percentage | |||||||||||||||||||||||||||||||
(Dollars in thousands) | Q2 2011 | Q2 2010 | Change | Change | YTD 2011 | YTD 2010 | Change | Change | ||||||||||||||||||||||||
Research and development |
$ | 50,801 | $ | 43,667 | $ | 7,134 | 16 | % | $ | 101,001 | $ | 87,343 | $ | 13,658 | 16 | % | ||||||||||||||||
Selling, general and administrative |
69,233 | 53,135 | 16,098 | 30 | 134,894 | 103,414 | 31,480 | 30 | ||||||||||||||||||||||||
Acquisition related expense, net |
4,770 | 1,861 | 2,909 | 156 | 5,040 | 1,861 | 3,179 | 171 | ||||||||||||||||||||||||
Headquarter relocation expense |
2,542 | | 2,542 | 100 | 5,064 | | 5,064 | 100 | ||||||||||||||||||||||||
Total operating expense |
$ | 127,346 | $ | 98,663 | $ | 28,683 | 29 | % | $ | 245,999 | $ | 192,618 | $ | 53,381 | 28 | % | ||||||||||||||||
Percentage | Percentage | |||||||||||||||||||||||||||||||
(Dollars in thousands) | Q2 2011 | Q2 2010 | Change | Change | YTD 2011 | YTD 2010 | Change | Change | ||||||||||||||||||||||||
Interest income |
$ | 1,981 | $ | 1,751 | $ | 230 | 13 | % | $ | 3,521 | $ | 3,955 | $ | (434 | ) | (11 | )% | |||||||||||||||
Interest expense |
(9,418 | ) | (6,134 | ) | (3,284 | ) | 54 | (16,809 | ) | (12,089 | ) | (4,720 | ) | 39 | ||||||||||||||||||
Other (expense) income, net |
(9,549 | ) | 3,481 | (13,030 | ) | (374 | ) | (37,078 | ) | 2,369 | (39,447 | ) | (1,665 | ) | ||||||||||||||||||
Total other expense, net |
$ | (16,986 | ) | $ | (902 | ) | $ | (16,084 | ) | 1783 | % | $ | (50,366 | ) | $ | (5,765 | ) | $ | (44,601 | ) | 774 | % | ||||||||||
22
Percentage | Percentage | |||||||||||||||||||||||||||||||
(Dollars in thousands) | Q2 2011 | Q2 2010 | Change | Change | YTD 2011 | YTD 2010 | Change | Change | ||||||||||||||||||||||||
Income before income taxes |
$ | 49,024 | $ | 46,526 | $ | 2,498 | 5 | % | $ | 85,032 | $ | 79,886 | $ | 5,146 | 6 | % | ||||||||||||||||
Provision for income taxes |
$ | 18,404 | $ | 16,730 | $ | 1,674 | 10 | $ | 30,275 | $ | 28,882 | $ | 1,393 | 5 | ||||||||||||||||||
Effective tax rate |
37.5 | % | 36.0 | % | 35.6 | % | 36.2 | % |
(In thousands) | YTD 2011 | YTD 2010 | ||||||
Net cash provided by operating activities |
$ | 159,798 | $ | 136,264 | ||||
Net cash used in investing activities |
(425,140 | ) | (121,124 | ) | ||||
Net cash provided by financing activities |
276,998 | 77,522 | ||||||
Effect of exchange rate changes on cash and cash equivalents |
481 | (108 | ) | |||||
Net increase in cash and cash equivalents |
$ | 12,137 | $ | 92,554 | ||||
23
24
| potential strategic acquisitions and investments; | ||
| support of our commercialization efforts related to our current and future products, including expansion of our direct sales force and field support resources both in the United States and abroad; | ||
| the repurchase of our outstanding common stock; | ||
| the continued advancement of research and development efforts; | ||
| the acquisition of equipment and other fixed assets for use in our current and future manufacturing and research and development facilities; and | ||
| the expansion needs of our facilities, including costs of leasing additional facilities. |
| our ability to successfully commercialize and further develop our technologies and create innovative products in our markets; | ||
| scientific progress in our research and development programs and the magnitude of those programs; | ||
| competing technological and market developments; and | ||
| the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and service offerings. |
25
| our ability to develop and commercialize further our sequencing, array, PCR, and consumables technologies and to deploy new sequencing, genotyping, gene expression, and diagnostics products and applications for our technology platforms; | ||
| our ability to manufacture robust instrumentation and consumables; | ||
| reductions in the funding levels to our primary customers; | ||
| our expectations and beliefs regarding future conduct and growth of the business; | ||
| our ability to maintain our revenue and profitability during periods of adverse economic and business conditions; | ||
| the assumptions underlying our Critical Accounting Policies and Estimates, including our estimates regarding stock volatility and other assumptions used to estimate the fair value of share-based compensation; the fair value of goodwill; and expected future amortization of acquired intangible assets; | ||
| our belief that the investments we hold are not other-than-temporarily impaired; | ||
| our assessments and estimates that determine our effective tax rate; | ||
| our belief that our cash and cash equivalents, investments and cash generated from operations will be sufficient to meet our working capital, capital expenditures and other liquidity requirements for at least the next 12 months | ||
| our assessments and beliefs regarding the future outcome of pending legal proceedings and the liability, if any, that Illumina may incur as a result of those proceeding. |
26
Total Number of | Approximate Dollar | |||||||||||||||
Shares Purchased as | Value of Shares | |||||||||||||||
Total Number of | Part of Publicly | that May Yet Be | ||||||||||||||
Shares | Average Price | Announced | Purchased Under | |||||||||||||
Period | Purchased (1) | Paid per Share | Programs | the Programs | ||||||||||||
April 4, 2011 May 1, 2011 |
118,546 | $ | 67.46 | 118,546 | $ | 123,994,935 | ||||||||||
May 2, 2011 May 29, 2011 |
110,799 | 72.20 | 110,799 | 115,992,572 | ||||||||||||
May 30, 2011 July 3, 2011 |
164,689 | 72.86 | 164,689 | 103,989,190 | ||||||||||||
Total |
394,034 | $ | 71.05 | 394,034 | $ | 103,989,190 | ||||||||||
27
(1) | All shares purchased during the three month ended July 3, 2011 were in connection with our stock repurchase program authorized by our board of directors in July 2010. All stock repurchases were made under a 10b5-1 trading program or in open-market transactions. |
28
Exhibit Number | Description of Document | |
31.1
|
Certification of Jay T. Flatley pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
31.2
|
Certification of Christian O. Henry pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
32.1
|
Certification of Jay T. Flatley pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
32.2
|
Certification of Christian O. Henry pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
101.INS
|
XBRL Instance Document | |
101.SCH
|
XBRL Taxonomy Extension Schema | |
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase | |
101.LAB
|
XBRL Taxonomy Extension Label Linkbase | |
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase | |
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase |
29
Illumina, Inc. (registrant) |
||||
Date: August 10, 2011 | /s/ CHRISTIAN O. HENRY | |||
Christian O. Henry | ||||
Senior Vice President and Chief Financial Officer | ||||
30
1. | I have reviewed this Quarterly Report on Form 10-Q of Illumina, Inc.; | ||
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; | ||
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; | ||
4. | The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | ||
b) | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | ||
c) | evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | ||
d) | disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and |
5. | The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions): |
a) | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and | ||
b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. |
Dated: August 10, 2011 | /s/ JAY T. FLATLEY | |||
Jay T. Flatley | ||||
President and Chief Executive Officer |
1. | I have reviewed this Quarterly Report on Form 10-Q of Illumina, Inc.; | ||
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; | ||
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; | ||
4. | The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | ||
b) | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | ||
c) | evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | ||
d) | disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and |
5. | The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions): |
a) | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and | ||
b) | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. |
Dated: August 10, 2011 | /s/ CHRISTIAN O. HENRY | |||
Christian O. Henry | ||||
Senior Vice President and Chief Financial Officer |
Dated: August 10, 2011 | By: | /s/ JAY T. FLATLEY | ||
Jay T. Flatley | ||||
President and Chief Executive Officer | ||||
Dated: August 10, 2011 | By: | /s/ CHRISTIAN O. HENRY | ||
Christian O. Henry | ||||
Senior Vice President and Chief Financial Officer | ||||
Condensed Consolidated Statements of Income (Unaudited) (USD $)
In Thousands, except Per Share data |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jul. 03, 2011
|
Jul. 04, 2010
|
Jul. 03, 2011
|
Jul. 04, 2010
|
|
Revenue: | ||||
Product revenue | $ 269,871 | $ 198,538 | $ 536,588 | $ 372,217 |
Service and other revenue | 17,579 | 13,465 | 33,377 | 31,917 |
Total revenue | 287,450 | 212,003 | 569,965 | 404,134 |
Cost of revenue: | ||||
Cost of product revenue | 84,518 | 59,627 | 169,955 | 112,566 |
Cost of service and other revenue | 6,541 | 4,690 | 12,593 | 10,084 |
Amortization of acquired intangible assets | 3,035 | 1,595 | 6,020 | 3,215 |
Total cost of revenue | 94,094 | 65,912 | 188,568 | 125,865 |
Gross profit | 193,356 | 146,091 | 381,397 | 278,269 |
Operating expense: | ||||
Research and development | 50,801 | 43,667 | 101,001 | 87,343 |
Selling, general and administrative | 69,233 | 53,135 | 134,894 | 103,414 |
Acquisition related expense, net | 4,770 | 1,861 | 5,040 | 1,861 |
Headquater relocation expense | 2,542 | 5,064 | ||
Total operating expense | 127,346 | 98,663 | 245,999 | 192,618 |
Income from operations | 66,010 | 47,428 | 135,398 | 85,651 |
Other income (expense): | ||||
Interest income | 1,981 | 1,751 | 3,521 | 3,955 |
Interest expense | (9,418) | (6,134) | (16,809) | (12,089) |
Other (expense) income, net | (9,549) | 3,481 | (37,078) | 2,369 |
Total other expense, net | (16,986) | (902) | (50,366) | (5,765) |
Income before income taxes | 49,024 | 46,526 | 85,032 | 79,886 |
Provision for income taxes | 18,404 | 16,730 | 30,275 | 28,882 |
Net income | $ 30,620 | $ 29,796 | $ 54,757 | $ 51,004 |
Net income per basic share | $ 0.25 | $ 0.24 | $ 0.44 | $ 0.42 |
Net income per diluted share | $ 0.22 | $ 0.21 | $ 0.37 | $ 0.37 |
Shares used in calculating basic net income per share | 123,456 | 123,095 | 124,987 | 121,882 |
Shares used in calculating diluted net income per share | 141,765 | 140,951 | 147,447 | 138,682 |
Stockholders' Equity (Tables)
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 03, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders' Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock option activity |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restricted stock unit activity |
|
Document and Entity Information (USD $)
|
6 Months Ended | ||
---|---|---|---|
Jul. 03, 2011
|
Jul. 15, 2011
|
Jul. 04, 2010
|
|
Document And Entity Information [Abstract] | |||
Entity Registrant Name | ILLUMINA INC | ||
Entity Central Index Key | 0001110803 | ||
Document Type | 10-Q | ||
Document Period End Date | Jul. 03, 2011 | ||
Amendment Flag | false | ||
Document Fiscal Year Focus | 2011 | ||
Document Fiscal Period Focus | Q2 | ||
Current Fiscal Year End Date | --01-01 | ||
Entity Well Known Seasoned Issuer | Yes | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Filer Category | Large Accelerated Filer | ||
Entity Public Float | $ 3,554,527,753 | ||
Entity Common Stock Shares Outstanding | 124,339,763 |
Summary of Significant Accounting Principles (Details Textual) (USD $)
|
3 Months Ended | 6 Months Ended |
---|---|---|
Jul. 03, 2011
|
Jul. 03, 2011
|
|
Summary of Significant Accounting Principles (Textuals) [Abstract] | ||
Total notional amount of outstanding forward contract in place for foreign currency purchase | $ 27,800,000 | $ 27,800,000 |
Headquarter relocation expenses represent accelerated depreciation expense, double-rent expense and cease-use loss | $ 2,542,000 | $ 5,064,000 |
"+ text.join( "
\n" ) +"
" + text[p] + "
\n"; } } }else{ formatted = '' + raw + '
'; } html = ''+ "\n"+''+ "\n"+''+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+' | '+ "\n"+'
'+ "\n"+' | '+ "\n"+' '+ "\n"+'
'+ "\n"+' | '+ "\n"+' '+ "\n"+'
Stockholders' Equity
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 03, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders' Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders' Equity |
8. Stockholders’ Equity
Stock Options
The Company’s stock option activity under all stock option plans during the six months ended
July 3, 2011 is as follows:
At July 3, 2011, outstanding options to purchase approximately 6,414,000 shares were
exercisable with a weighted average per share exercise price of $21.11.
Employee Stock Purchase Plan
The price at which common stock is purchased under the ESPP is equal to 85% of the fair market
value of the common stock on the first or last day of the offering period, whichever is lower.
Shares totaling 184,000 were issued under the ESPP during the six months ended July 3, 2011. As of
July 3, 2011, there were approximately 15,878,000 shares available for issuance under the ESPP.
Restricted Stock Units
A summary of the Company’s restricted stock unit activity and related information for the six
months ended July 3, 2011 is as follows:
Warrants
In conjunction with an acquisition in January 2007, the Company assumed a certain number of
warrants, the majority of which were exercised in periods prior to 2011. During the first quarter
of 2011, the remaining assumed warrants to purchase approximately 505,000 shares of the Company’s
common stock were exercised, resulting in cash proceeds to the Company of approximately $5.5
million. As of July 3, 2011, warrants to purchase approximately 18,322,000 shares of common stock
were outstanding with an exercise price of $31.44, which were all sold in connection with the
offering of the Company’s 2014 Notes as discussed in note “6. Convertible Senior Notes.” All
outstanding warrants expire on February 15, 2014.
Share Repurchases
In July 2010, the Company’s board of directors authorized a $200 million stock repurchase
program, with $100 million allocated to repurchasing Company common stock under a 10b5-1 plan over
a 12 month period and $100 million allocated to repurchasing Company common stock at management’s
discretion during open trading windows. During the three and six months ended July 3, 2011, the
Company repurchased approximately 394,000 shares for $28.0 million and 746,000 shares for $52.0
million, respectively, under the program authorized in July 2010. The stock repurchase program of
$100 million under the 10b5-1 plan was completed on July 12, 2011. As of July 3, 2011, none of the
$100 million discretionary repurchase approved had been utilized by management; however, the July 2010
authorized $100 million discretionary repurchase has been subsequently utilized in its entirety by August 1, 2011.
Additionally, the Company’s board of directors authorized a new $100 million discretionary repurchase program in
August 2011.
In addition, on March 18, 2011, concurrently with the issuance of the Company’s 2016 Notes,
4,890,500 shares were repurchased for $314.3 million.
|
Stockholders' Equity (Details) (USD $)
In Thousands, except Per Share data |
6 Months Ended |
---|---|
Jul. 03, 2011
|
|
Stock option activity | |
Options, Outstanding at January 2, 2011 | 11,882 |
Options, Granted | 1,226 |
Options, Exercised | (2,124) |
Options, Cancelled | (34) |
Options, Outstanding at July 3, 2011 | 10,950 |
Weighted-Average Exercise Price, Outstanding at January 2, 2011 | $ 22.83 |
Weighted Average Exercise Price, Granted | $ 70.06 |
Weighted Average Exercise Price, Exercised | $ 17.41 |
Weighted Average Exercise Price, Cancelled | $ 21.17 |
Weighted-Average Exercise Price, Outstanding at July 3, 2011 | $ 29.17 |
Weighted Average Grant Date Fair Value per Share, Outstanding at January 2, 2011 | $ 12.82 |
Weighted Average Grant Date Fair Value per Share, Granted | $ 29.53 |
Weighted Average Grant Date Fair Value per Share, Exercised | $ 10.29 |
Weighted Average Grant Date Fair Value per Share, Cancelled | $ 13.36 |
Weighted Average Grant Date Fair Value per Share, Outstanding at July 3, 2011 | $ 15.18 |
Summary of Significant Accounting Principles (Details 1) (USD $)
In Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jul. 03, 2011
|
Jul. 04, 2010
|
Jul. 03, 2011
|
Jul. 04, 2010
|
|
Comprehensive income | ||||
Net income | $ 30,620 | $ 29,796 | $ 54,757 | $ 51,004 |
Unrealized gain (loss) on available-for-sale securities, net of deferred tax | 1,227 | (39) | 582 | (217) |
Total comprehensive income | $ 31,847 | $ 29,757 | $ 55,339 | $ 50,787 |
Balance Sheet Account Details (Tables)
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 03, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance Sheet Account Details [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Short-term Investments |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Available-for-sale securities in an unrealized loss position |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contractual maturities of available-for-sale securities |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory, net |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued liabilities |
|
Fair Value Measurement
|
6 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 03, 2011
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurement [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurement |
4. Fair Value Measurements
The following table presents the Company’s hierarchy for assets and liabilities measured at
fair value on a recurring basis as of July 3, 2011 and January 2, 2011 (in thousands):
The Company measures the fair value of debt securities in government sponsored entities and
corporate debt securities on a recurring basis primarily using quoted prices for similar assets in
active markets.
At July 3, 2011, the Company reassessed the fair value of the contingent consideration settled
in cash related to acquisitions using the income approach. These fair value measurements are Level
3 measurements. Significant assumptions used in the measurement include probabilities of achieving
the remaining milestones and the discount rates, which depends on the
milestone risk profiles. Due to changes in the estimated probabilities to achieve the relevant
milestones and a shorter discounting period, the fair value of the contingent consideration
liabilities changed, resulting in a gain of $0.7 million and $0.4 million recorded in selling,
general and administrative expenses in the consolidated statements of income during the three and
six months ended July 3, 2011, respectively.
Changes in estimated fair value of contingent consideration liabilities from January 2, 2011
through July 3, 2011 are as follows (in thousands):
|
Fair Value Measurements [Details] (USD $)
In Thousands |
3 Months Ended | 6 Months Ended | |
---|---|---|---|
Jul. 03, 2011
|
Jul. 03, 2011
|
Jan. 02, 2011
|
|
Assets: | |||
Money market funds (cash equivalent) | $ 172,360 | $ 172,360 | $ 148,822 |
Total assets measured at fair value | 1,145,190 | 1,145,190 | 794,164 |
Liability: | |||
Contingent consideration | 10,760 | 10,760 | |
Change in estimated fair value of the contingent consideration liability | |||
Balance as of January 2, 2011 | 3,738 | ||
Acquisition of Epicentre | 7,400 | ||
Gain recorded in acquisition related expense, net | 700 | 378 | |
Balance as of July 3, 2011 | 10,760 | 10,760 | |
Debt securities in government sponsored entities [Member]
|
|||
Assets: | |||
Investments, fair value disclosure | 437,720 | 437,720 | 261,697 |
Debt securities in government sponsored entities [Member] | Fair Value, Inputs, Level 2 [Member]
|
|||
Assets: | |||
Investments, fair value disclosure | 437,720 | 437,720 | 261,697 |
Corporate debt securities [Member]
|
|||
Assets: | |||
Investments, fair value disclosure | 485,864 | 485,864 | 330,758 |
Corporate debt securities [Member] | Fair Value, Inputs, Level 2 [Member]
|
|||
Assets: | |||
Investments, fair value disclosure | 485,864 | 485,864 | 330,758 |
U.S. Treasury securities [Member]
|
|||
Assets: | |||
Investments, fair value disclosure | 49,246 | 49,246 | 52,887 |
U.S. Treasury securities [Member] | Fair Value, Inputs, Level 1 [Member]
|
|||
Assets: | |||
Investments, fair value disclosure | 49,246 | 49,246 | 52,887 |
Fair Value, Inputs, Level 1 [Member]
|
|||
Assets: | |||
Money market funds (cash equivalent) | 172,360 | 172,360 | 148,822 |
Total assets measured at fair value | 221,606 | 221,606 | 201,709 |
Fair Value, Inputs, Level 2 [Member]
|
|||
Assets: | |||
Total assets measured at fair value | 923,584 | 923,584 | 592,455 |
Fair Value, Inputs, Level 3 [Member]
|
|||
Liability: | |||
Contingent consideration | 10,760 | 10,760 | 3,738 |
Change in estimated fair value of the contingent consideration liability | |||
Balance as of January 2, 2011 | 3,738 | ||
Balance as of July 3, 2011 | $ 10,760 | $ 10,760 | $ 3,738 |
Legal Proceedings
|
6 Months Ended |
---|---|
Jul. 03, 2011
|
|
Legal Proceedings [Abstract] | |
Legal Proceedings |
10. Legal Proceedings
The Company is involved in various lawsuits and claims arising in the ordinary
course of business. Because of the uncertainties related to
the occurrence, amount, and range of loss on any pending litigation
or claim, management is currently unable to predict their
ultimate outcome, to determine whether a liability has been incurred,
or to make a meaningful
estimate of the reasonably possible loss or range of loss that could
result from an unfavorable outcome. The Company believes, however, that the liability,
if any, resulting from the aggregate amount of losses for any outstanding
litigation or claim will not have a material adverse effect on the
Company’s consolidated financial position, liquidity, or results of operations.
|
Fair Value Measurements (Tables)
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 03, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurement [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair value measurements |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Changes in fair value of contingent consideration liabilities |
|
Summary of Significant Accounting Principles (Policies)
|
6 Months Ended | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Jul. 03, 2011
|
||||||||||
Summary of Significant Accounting Principles [Abstract] | ||||||||||
Basis of Presentation |
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in
accordance with U.S. generally accepted accounting principles (GAAP) for interim financial
information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they
do not include all of the information and footnotes required by GAAP for complete financial
statements. The unaudited condensed consolidated financial statements include the accounts of the
Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been
eliminated in consolidation. In management’s opinion, the accompanying financial statements reflect
all adjustments, consisting of normal recurring adjustments, considered necessary for a fair
presentation of the results for the interim periods presented.
Interim financial results are not necessarily indicative of results anticipated for the full
year. These unaudited financial statements should be read in conjunction with the Company’s audited
financial statements and footnotes included in the Company’s Annual Report on Form 10-K for the
fiscal year ended January 2, 2011 from which the balance sheet information herein was derived.
The preparation of financial statements requires that management make estimates and
assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and
related disclosure of contingent assets and liabilities. Actual results could differ from those
estimates.
|
|||||||||
Fiscal Year |
Fiscal Year
The Company’s fiscal year consists of 52 or 53 weeks ending the Sunday closest to December 31,
with quarters of 13 or 14 weeks ending the Sunday closest to March 31, June 30, September 30, and
December 31. The three and six months ended July 3, 2011 and July 4, 2010 were both 13 and 26
weeks, respectively.
|
|||||||||
Reclassifications |
Reclassifications
Certain prior period amounts have been reclassified to conform to the current year
presentation.
|
|||||||||
Revenue Recognition |
Revenue Recognition
The Company’s revenue is generated primarily from the sale of products and services. Product
revenue primarily consists of sales of instrumentation and consumables used in genetic analysis.
Service and other revenue primarily consists of revenue generated from instrument service
contracts, genotyping and sequencing services, and research agreements with government grants.
The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has
occurred or services have been rendered, the price is fixed or determinable, and collectibility is
reasonably assured. In instances where final acceptance of the product is required, revenue is
deferred until all the acceptance criteria have been met. All revenue is recorded net of
discounts.
Revenue for product sales is recognized generally upon transfer of title to the customer,
provided that no significant obligations remain and collection of the receivable is reasonably
assured. Revenue from instrument service contracts is recognized as the services are rendered,
typically evenly over the contract term, and revenue from genotyping and sequencing services is
recognized when earned, which is generally at the time the genotyping or sequencing analysis data
is made available to the customer or agreed upon milestones are
reached. Revenue from research agreements
with government grants is recognized in the period during which the related costs are incurred.
In order to assess whether the price is fixed or determinable, the Company evaluates whether
refund rights exist. If there are refund rights or payment terms based on future performance, the
Company defers revenue recognition until the price becomes fixed or determinable. The Company
assesses collectibility based on a number of factors, including past transaction history with the
customer and the creditworthiness of the customer. If the Company determines that collection of a
payment is not reasonably assured, revenue recognition is deferred until receipt of payment.
The Company regularly enters into contracts where revenue is derived from multiple
deliverables including any mix of products or services. These products or services are generally
delivered within a short time frame, approximately three to six months, after the contract
execution date. Revenue recognition for contracts with multiple deliverables is based on the
individual units of accounting determined to exist in the contract. A delivered item is considered
a separate unit of accounting when the delivered item has value to the customer on a stand-alone
basis. Items are considered to have stand-alone value when they are sold separately by any vendor
or when the customer could resell the item on a stand-alone basis. Consideration is allocated at
the inception of the contract to all deliverables based on their relative selling price. The
relative selling price for each deliverable is determined using vendor specific objective evidence
(VSOE) of selling price or third-party evidence of selling price if VSOE does not exist. If neither
VSOE nor third-party evidence exists, the Company uses its best estimate of the selling price for
the deliverable.
In order to establish VSOE of selling price, the Company must regularly sell the product or
service on a stand-alone basis with a substantial majority priced within a relatively narrow range.
VSOE of selling price is usually the midpoint of that range. If there are not a sufficient number
of standalone sales and VSOE of selling price cannot be determined, then the Company considers
whether third party evidence can be used to establish selling price. Due to the lack of similar
products and services sold by other companies within the industry, the Company has rarely
established selling price using third-party evidence. If neither VSOE nor third party evidence of
selling price exists, the Company determines its best estimate of selling price using average
selling prices over a rolling 12-month period coupled with an assessment of current market
conditions. If the product or service has no history of sales or if the sales volume is not
sufficient, the Company relies upon prices set by the Company’s pricing committee adjusted for
applicable discounts. The Company recognizes revenue for delivered elements only when it determines
there are no uncertainties regarding customer acceptance.
In the first quarter of 2010, the Company offered an incentive with the HiSeq 2000 launch that
enabled existing Genome Analyzer customers to trade in their Genome Analyzer and receive a discount
on the purchase of a HiSeq 2000. The incentive was limited to customers who had purchased a Genome
Analyzer as of the date of the announcement and was the first significant trade-in program offered
by the Company. The Company accounts for HiSeq 2000 discounts related to the Genome Analyzer
trade-in program as reductions to revenue upon recognition of the HiSeq 2000 sales revenue, which
is later than the date the trade-in program was launched.
In certain markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and
South Africa, the Company sells products and provides services to customers through distributors
that specialize in life science products. In most sales through distributors, the product is
delivered directly to customers. In cases where the product is delivered to a distributor, revenue
recognition is deferred until acceptance is received from the distributor, and/or the end-user, if
required by the applicable sales contract. The terms of sales transactions through distributors are
consistent with the terms of direct sales to customers. These transactions are accounted for in
accordance with the Company’s revenue recognition policy described herein.
|
|||||||||
Goodwill, Intangible Assets and Other Long-Lived Assets |
Goodwill, Intangible Assets, and Other Long-Lived Assets
Goodwill represents the excess of cost over fair value of net assets acquired. The change in
the carrying value of goodwill during the six months ended July 3, 2011 was due to goodwill
recorded in connection with the Company’s acquisition of Epicentre Technologies Corporation
(Epicentre) in January 2011.
The Company’s identifiable intangible assets are comprised primarily of in-process research
and development (IPR&D), licensed technology, acquired core technologies, customer relationships,
trade names, and license agreements. Except IPR&D, the cost of all identifiable intangible assets is
amortized on a straight-line basis over their respective useful lives. The Company regularly
performs reviews to determine if the carrying values of its long-lived assets are impaired. A
review of intangible assets that have finite useful lives and other long-lived assets is performed
when an event occurs indicating the potential for impairment. If indicators of impairment exist,
the Company assesses the recoverability of the affected long-lived assets by determining whether
the carrying amount of such assets exceeds the undiscounted expected future cash flows associated
with such assets. If impairment is indicated, the Company compares the carrying amount to the
estimated fair value of the affected assets and adjusts the value of such assets accordingly.
Factors that would necessitate an impairment assessment include a significant decline in the
Company’s stock price and market capitalization compared to its net book value, significant changes
in the ability of a particular asset to generate positive cash flows, and significant changes in
the Company’s strategic business objectives and utilization of a particular asset. The Company
performed quarterly reviews of its long-lived assets and noted no indications of impairment for the
three and six months ended July 3, 2011.
Goodwill and IPR&D, which have indefinite useful lives, are reviewed for impairment at least
annually during the second fiscal quarter, or more frequently if an event occurs indicating the
potential for impairment. The performance of the goodwill impairment test is a two-step process.
The first step of the impairment test involves comparing the estimated fair value of the reporting
unit with its carrying value, including goodwill. If the carrying amount of the reporting unit
exceeds its fair value, the Company performs the second step of the goodwill impairment test to
determine the amount of loss, which involves comparing the implied fair value of the goodwill with
the carrying value of the goodwill. The Company performed its annual impairment test of goodwill in
the second fiscal quarter of 2011, noting no impairment. In its impairment test, the Company
concluded that it has a single reporting unit and that its fair value exceeded its book value,
using market capitalization as a reference for the Company’s fair value. Therefore, the first step
recoverability test was passed and the second step analysis was not required.
The IPR&D impairment test requires the Company to assess the fair value of the asset
as compared to its carrying value, and if the carrying value exceeds the fair value, record an impairment
charge. The Company performed its annual impairment test of its IPR&D in the second fiscal quarter
of 2011, noting no impairment. In its impairment test, the Company assessed the fair value of IPR&D
using an income approach, taking into consideration various factors such as future revenue
contributions, additional research and development costs to be incurred, and contributory asset
charges. The rate used to discount net future cash flows to their present values was based on a
risk-adjusted rate of return.
|
|||||||||
Fair Value Measurements |
Fair Value Measurements
The Company determines the fair value of its assets and liabilities based on the exchange
price that would be received for an asset or paid to transfer a liability (an exit price) in the
principal or most advantageous market for the asset or liability in an orderly transaction between
market participants on the measurement date. Valuation techniques used to measure fair value
maximize the use of observable inputs and minimize the use of unobservable inputs. The Company uses
a fair value hierarchy with three levels of inputs, of which the first two are considered
observable and the last unobservable, to measure fair value:
The carrying amounts of financial instruments such as cash and cash equivalents, accounts
receivable, prepaid expenses and other current assets, accounts payable, and accrued liabilities,
excluding acquisition related contingent consideration liabilities, approximate the related fair
values due to the short-term maturities of these instruments.
|
|||||||||
Derivatives |
Derivatives
The Company is exposed to foreign exchange rate risks in the normal course of business. To
manage a portion of the accounting exposure resulting from changes in foreign currency exchange
rates, the Company enters into foreign exchange contracts to hedge monetary assets and liabilities
that are denominated in currencies other than the United States dollar. These foreign exchange
contracts are carried at fair value, do not qualify for hedge accounting treatment, and are not
designated as hedging instruments. Changes in the value of the foreign exchange contracts are
recognized in other (expense) income, net, in the consolidated statements of income for the current period,
along with an offsetting gain or loss on the underlying assets or liabilities.
As of July 3, 2011, the Company had foreign exchange forward contracts in place to hedge
exposures in the euro, Japanese yen, and Australian dollar. As of July 3, 2011, the total notional
amount of outstanding forward contracts in place for foreign currency purchases was approximately
$27.8 million. Losses related to the non-designated foreign exchange forward contracts for the
three and six months ended July 3, 2011 were immaterial.
|
|||||||||
Leases |
Leases
Leases are reviewed and classified as capital or operating at their inception. For leases that
contain rent escalations, the Company records rent expense on a straight-line basis over the term
of the lease, which includes the construction build-out period and lease extension periods, if
appropriate. The difference between rent payments and straight-line rent expense is recorded as
deferred rent in
other long-term liabilities. Landlord allowances are recorded in other long-term
liabilities and amortized on a straight-line basis over the lease term as a reduction to
rent expense. The Company capitalizes leasehold improvements and amortizes them over the shorter of
the lease term or their expected useful lives.
In December 2010, the Company agreed to lease a facility in San Diego, California that will
serve as its new corporate headquarters. Headquarter relocation expense
is recorded in the Company’s operating expenses and includes a cease-use loss to be recorded upon vacating its
current headquarter facility expected near the end of 2011, additional rent expense during the
transition to the new facility, and accelerated depreciation of certain property and equipment. The
cease-use loss will be calculated as the present value of the expected difference between the
remaining lease payments obligation and estimated sublease rental during the remaining lease
period, adjusted for deferred rent and leasehold improvements. The Company will record rent expense
upon obtaining control of the new facility, and as a result, will incur additional rent expense
until vacating the current facility. In addition, the Company records accelerated depreciation
expense for leasehold improvements at its current headquarter facility based on the reassessed
useful lives of less than a year. Headquarter relocation expense of $2.5 million and $5.1 million
recorded in the three and six months ended July 3, 2011 represent accelerated depreciation expense.
|
|||||||||
Net Income per Share |
Net Income per Share
Basic net income per share is computed by dividing net income by the weighted average number
of common shares outstanding during the reporting period. Diluted net income per share is computed
by dividing net income by the weighted average number of common shares outstanding during the
reporting period increased to include dilutive potential common shares calculated using the
treasury stock method. Diluted net income per share reflects the potential dilution from
outstanding stock options, restricted stock units, employee stock purchase plan (ESPP), warrants,
shares subject to forfeiture, and convertible senior notes. Under the treasury stock method,
convertible senior notes will have a dilutive impact when the average market price of the Company’s
common stock is above the applicable conversion price of the respective notes. In addition, the
following amounts are assumed to be used to repurchase shares: the amount that must be paid to
exercise stock options and warrants and purchase shares under the ESPP; the amount of compensation
expense for future services that the Company has not yet recognized for stock options, restricted
stock units, ESPP, and shares subject to forfeiture; and the amount of tax benefits that will be
recorded in additional paid-in capital when the expenses related to respective awards become
deductible.
|
|||||||||
Comprehensive Income |
Comprehensive Income
|
|||||||||
Recent Accounting Pronouncements |
Recent Accounting Pronouncements
In May 2011, the Financial Accounting Standards Board (FASB) issued an amendment to the Fair value Measurements and Disclosures topic of the Accounting Standards Codification (ASC). The amendment
clarifies the application of certain existing fair value measurement guidance and
expands the disclosures for fair value measurements that are estimated using significant
unobservable (Level 3) inputs. This amendment is effective for the Company in first quarter of fiscal
2012. The amendment is to be adopted prospectively and early adoption is not permitted. The
Company does not believe that adoption of the amendment will have a significant impact on its
financial position, results of operations, or cash flows.
In June 2011, the FASB issued an update to the Comprehensive Income topic of the ASC. This update requires an
entity to present the total of comprehensive income, the components of net income, and the
components of other comprehensive income either in a single continuous statement of comprehensive
income or in two separate but consecutive statements. This update eliminates the option to present
the components of other comprehensive income as part of the statement of equity. It is
effective for the Company in first quarter of fiscal 2012 and should be applied retrospectively.
The update is to be adopted prospectively and early adoption is permitted. The Company does
not believe that adoption of this update will have an impact on its financial position, results of
operations, or cash flows.
|
Acquisitions (Details 1) (USD $)
In Thousands |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jul. 03, 2011
|
Jul. 04, 2010
|
Jul. 03, 2011
|
Jul. 04, 2010
|
|
Contingent compensation expense [Abstract] | ||||
Contingent Compensation Expense Included In Research and Development expense | $ 1,855 | $ 919 | $ 3,292 | $ 1,838 |
Contingent compensation expense,included in selling, general and administrative expense | 851 | 0 | 1,538 | 0 |
Contingent compensation expense | 2,706 | 919 | 4,830 | 1,838 |
IPR&D, included in research and development expense | $ 5,425 | $ 1,325 | $ 5,425 | $ 1,325 |
Income Taxes
|
6 Months Ended |
---|---|
Jul. 03, 2011
|
|
Income Taxes [Abstract] | |
Income Taxes |
9. Income Taxes
The Company’s effective tax rate may vary from the U.S statutory tax rate due to the change in
the mix of earnings in tax jurisdictions with different statutory rates, benefits related to tax
credits, and the tax impact of non-deductible expenses and other permanent differences between
income before income taxes and taxable income. The effective tax rates for the three and six months
ended July 3, 2011 were 37.5% and 35.6%, respectively. For the three and six months ended July 3,
2011, the variance from the U.S statutory rate of 35% is primarily attributable to the tax
detriment related to non-deductible additional IPR&D charges recorded in
acquisition related expense, net, partially offset by the tax benefit related to the loss on
extinguishment of debt. Both items were recorded as discrete items.
|
Balance Sheet Account Details
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 03, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance Sheet Account Details [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance Sheet Account Details |
2. Balance Sheet Account Details
Short-Term Investments
The following is a summary of short-term investments (in thousands):
As of July 3, 2011, the Company had 101 available-for-sale securities in a gross unrealized
loss position, all of which had been in such position for less than twelve months. There were no
unrealized losses due to credit issues for the periods presented. There was no impairment
considered other-than-temporary as it is more likely than not the Company will hold the securities
until maturity or a recovery of the cost basis. The following table shows the fair values and the
gross unrealized losses of the Company’s available-for-sale securities that were in unrealized loss
positions as of July 3, 2011 and January 2, 2011 aggregated by investment category (in thousands):
Realized gains and losses are determined based on the specific identification method and are
reported in interest income in the consolidated statements of income. Gross realized gains and
losses on sales of available-for sale securities for the three and six months ended July 3, 2011
and July 4, 2010 were immaterial.
Contractual maturities of available-for-sale securities as of July 3, 2011 were as follows (in
thousands):
Inventory
Inventory, net, consists of the following (in thousands):
Cost-Method Investments
As of July 3, 2011 and January 2, 2011, the aggregate carrying amounts of the Company’s
cost-method investments in non-publicly traded companies were $38.4 million and $32.0 million,
respectively, which were included in other long term assets in the consolidated balance sheets. The
Company assesses all cost-method investments for impairment quarterly. No impairment loss was
recorded during the three and six months ended July 3, 2011 or July 4, 2010. The Company
does not reassess the fair value of cost-method investments if there are no identified events or
changes in circumstances that may have a significant adverse effect on the fair value of the
investments.
Accrued Liabilities
Accrued liabilities consist of the following (in thousands):
|
Warranties
|
6 Months Ended | |||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 03, 2011
|
||||||||||||||||||||||||||||||||||||
Warranties [Abstract] | ||||||||||||||||||||||||||||||||||||
Warranties |
5. Warranties
The Company generally provides a one-year warranty on instruments. Additionally, the Company
provides a warranty on its consumables through the expiration date, which generally ranges from six
to twelve months after the manufacture date. The Company establishes an accrual for estimated
warranty expenses based on historical experience as well as anticipated product performance. The
Company periodically reviews the adequacy of its warranty reserve and adjusts, if necessary, the
warranty percentage and accrual based on actual experience and estimated costs to be incurred.
Warranty expense is recorded as a component of cost of product revenue. Expenses associated with
instrument service contracts are recorded as a cost of service and other revenue as incurred.
Changes in the Company’s reserve for product warranties from January 2, 2011 through July 3,
2011 are as follows (in thousands):
|
Convertible Senior Notes (Details Textual) (USD $)
|
6 Months Ended | 3 Months Ended | 6 Months Ended | 3 Months Ended | 6 Months Ended | 3 Months Ended | 6 Months Ended | 3 Months Ended | 6 Months Ended | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 03, 2011
|
Jul. 04, 2010
|
Jul. 03, 2011
Maximum [Member]
0.625% Convertible senior notes due 2014 [Member]
|
Jul. 03, 2011
Maximum [Member]
0.625% Convertible senior notes due 2014 [Member]
|
Jul. 03, 2011
Minimum [Member]
0.625% Convertible senior notes due 2014 [Member]
|
Jul. 03, 2011
Minimum [Member]
0.625% Convertible senior notes due 2014 [Member]
|
Jul. 03, 2011
0.25% Convertible Senior Notes due 2016 [Member]
|
Jul. 03, 2011
0.25% Convertible Senior Notes due 2016 [Member]
|
Apr. 18, 2011
0.25% Convertible Senior Notes due 2016 [Member]
|
Mar. 18, 2011
0.25% Convertible Senior Notes due 2016 [Member]
|
Jul. 03, 2011
0.625% Convertible senior notes due 2014 [Member]
|
Jul. 03, 2011
0.625% Convertible senior notes due 2014 [Member]
|
Jan. 02, 2011
0.625% Convertible senior notes due 2014 [Member]
|
Feb. 16, 2007
0.625% Convertible senior notes due 2014 [Member]
|
|
Convertible Senior Notes (Textuals) [Abstract] | ||||||||||||||
Interest rate on convertible senior notes | 0.25% | 0.25% | 0.625% | |||||||||||
Debt issuance price as a percentage of principal | 0.9825 | |||||||||||||
Interest payments | $ 1,200,000 | |||||||||||||
Maximum shares entitles to purchase shares under hedge transaction upon issuance of the convertible senior notes | 18,322,320 | |||||||||||||
Maximum shares exercisable by counterparties warrants sold | 18,322,320 | |||||||||||||
Strike price of common shares under hedge transaction upon issuance of the convertible senior notes | $ 21.83 | $ 21.83 | ||||||||||||
Conversion Price | $ 83.55 | $ 83.55 | ||||||||||||
Strike price of warrants sold to hedge counterparties upon issuance of convertible notes | 31.435 | 31.435 | ||||||||||||
Debt issuance costs | 400,000 | 400,000 | ||||||||||||
Amount of Notes Offered to Initial Purchasers at their Option | 120,000,000 | |||||||||||||
Net initial issuance | 785,600,000 | |||||||||||||
Net Subsequent Issuance | 117,900,000 | |||||||||||||
Conversion rate per 1,000 principal amount of notes | 11.9687 | |||||||||||||
Circumstances of converting notes at referred conversion ratio | during the five business-day period after any 10 consecutive trading day period (the “measurement period”) in which the trading price per 2016 Note for each day of such measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such day; (2) during any calendar quarter (and only during that quarter) after the calendar quarter ending March 31, 2011, if the last reported sale price of the Company's common stock for 20 or more trading days in the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter exceeds 130% of the applicable conversion price in effect on the last trading day of the immediately preceding calendar quarter; (3) upon the occurrence of specified events described in the indenture for the 2016 Notes; and (4) at any time on or after December 15, 2015 through the second scheduled trading day immediately preceding the maturity date | |||||||||||||
Maximum payment on principal portion to be cash settled upon conversion | 1,000 | |||||||||||||
Principal amount used in calculating incremental share settlement amount | 1,000 | |||||||||||||
Estimated interest rate of convertible senior notes | 3.90% | 4.00% | 3.60% | 3.60% | 4.50% | |||||||||
Fair value of liability component | 748,500,000 | 748,500,000 | ||||||||||||
Principal amount of convertible notes outstanding | 920,000,000 | 920,000,000 | 49,090,000 | 49,090,000 | 389,999,000 | |||||||||
Carrying Amount of Equity Component | 155,366,000 | 155,366,000 | 112,039,000 | 112,039,000 | 71,199,000 | |||||||||
Cash proceeds | 903,900,000 | |||||||||||||
Interest expense | 600,000 | 700,000 | ||||||||||||
Accretion of discount on liability component | 15,185,000 | 10,504,000 | 7,600,000 | 8,800,000 | ||||||||||
Proceeds from Debt Issuance Used in Stock Repurchases | 314,300,000 | |||||||||||||
Purchase of number of shares | 4,890,500 | |||||||||||||
Cash paid for principal of notes converted | 340,909,000 | 87,774,000 | 340,909,000 | |||||||||||
Repurchase price as a percentage of principal amount upon designated events | 100.00% | |||||||||||||
Issuance of convertible senior notes | 800,000,000 | 400,000,000 | ||||||||||||
Unamortized discount | $ 162,726,000 | $ 162,726,000 | $ 8,441,000 | $ 8,441,000 | $ 78,390,000 | |||||||||
Remaining discount amortization period | 4.7 | 4.7 | 2.6 | 2.6 | 3.1 | |||||||||
Amortization period for debt issuance cost | 5 years |
Balance Sheet Account Details (Details Textual) (USD $)
|
3 Months Ended | 6 Months Ended | |||
---|---|---|---|---|---|
Jul. 03, 2011
|
Jul. 04, 2010
|
Jul. 03, 2011
|
Jul. 04, 2010
|
Jan. 02, 2011
|
|
Balance Sheet Account Details (Textuals) [Abstract] | |||||
Number of available-for-sale securities in a gross unrealized loss position | 101 | 101 | |||
Unrealized losses due to credit issues | $ 0 | $ 0 | $ 0 | ||
Impairment considered other-than-temporary | 0 | ||||
Company's cost-method investments in non-publicly traded company | 38,400,000 | 38,400,000 | 32,000,000 | ||
Impairment loss during the period | $ 0 | $ 0 | $ 0 | $ 0 |
Convertible Senior Notes
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 03, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Senior Notes [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Senior Notes |
6. Convertible Senior Notes
0.25% Convertible Senior Notes due 2016
On March 18, 2011, the Company issued $800 million aggregate principal amount of 0.25%
convertible senior notes due 2016 (the 2016 Notes) in an offering conducted in accordance with Rule
144A under the Securities Act of 1933, as amended. The 2016 Notes were issued at 98.25% of par
value. Debt issuance costs of approximately $0.4 million primarily comprised legal,
accounting, and other professional fees, the majority of which were recorded in other noncurrent
assets and are being amortized to interest expense over the five-year term of the 2016 Notes. The
Company granted to the initial purchasers of the 2016 Notes an option to purchase from the Company,
within 30 days, up to an additional $120 million aggregate principal amount of 2016 Notes, and on
April 18, 2011, the Company issued an additional $120 million principal amount of the 2016 Notes
pursuant to this option. The net proceeds from the initial issuance and subsequent issuance, after
deducting the initial purchasers’ discount and the estimated offering expenses payable by the
Company, were $785.6 million and $117.9 million, respectively.
The 2016 Notes will be convertible into cash, shares of common stock, or a combination of cash
and shares of common stock, at the Company’s election, based on an initial conversion rate, subject
to adjustment, of 11.9687 shares per $1,000 principal amount of the 2016 Notes (which represents an
initial conversion price of approximately $83.55 per share), only in the following circumstances
and to the following extent: (1) during the five business-day period after any 10 consecutive
trading day period (the “measurement period”) in which the trading price per 2016 Note for each day
of such measurement period was less than 98% of the product of the last reported sale price of the
Company’s common stock and the conversion rate on each such day; (2) during any calendar quarter
(and only during that quarter) after the calendar quarter ending March 31, 2011, if the last
reported sale price of the Company’s common stock for 20 or more trading days in the period of 30
consecutive trading days ending on the last trading day of the immediately preceding calendar
quarter exceeds 130% of the applicable conversion price in effect on the last trading day of the
immediately preceding calendar quarter; (3) upon the occurrence of specified events described in
the indenture for the 2016 Notes; and (4) at any time on or after December 15, 2015 through the
second scheduled trading day immediately preceding the maturity date.
As noted in the indenture for the 2016 Notes, it is the Company’s intent and policy to settle
conversions through combination settlement, which essentially involves repayment of an amount of
cash equal to the “principal portion” and delivery of the “share amount” in excess of the
conversion value over the principal portion in shares of common stock. In general, for each $1,000
in principal, the “principal portion” of cash upon settlement is defined as the lesser of $1,000,
and the conversion value during the 20-day observation period as described in the indenture for the
2016 Notes. The conversion value is the sum of the daily conversion value which is the product of
the effective conversion rate divided by 20 days and the daily volume weighted average price
(“VWAP”) of the Company’s common stock. The “share amount” is the cumulative “daily share amount”
during the observation period, which is calculated by dividing the daily VWAP into the difference
between the daily conversion value (i.e., conversion rate x daily VWAP) and $1,000.
The Company will pay 0.25% interest per annum on the principal amount of the 2016 Notes,
payable semiannually in arrears in cash on March 15 and September 15 of each year, beginning
September 15, 2011. The 2016 Notes mature on March 15, 2016. If a designated event, as defined in
the indenture for the 2016 Notes, occurs prior to the maturity date, subject to certain
limitations, holders of the 2016 Notes may require the Company to repurchase all or a portion of
their 2016 Notes for cash at a repurchase price equal to 100% of the principal amount of the 2016
Notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the repurchase
date.
The Company accounts separately for the liability and equity components of the 2016 Notes in
accordance with authoritative guidance for convertible debt instruments that may be settled in cash
upon conversion. The guidance requires the carrying amount of the liability component to be
estimated by measuring the fair value of a similar liability that does not have an associated
conversion feature. Because the Company has no outstanding non-convertible public debt, the Company
determined that senior, unsecured corporate bonds traded on the market represent a similar
liability to the convertible senior notes without the conversion option. Based on market data
available for publicly traded, senior, unsecured corporate bonds issued by companies in the same
industry and with similar maturity, the Company estimated the implied interest rate of its 2016
Notes to be 4.5%, assuming no conversion option. Assumptions used in the estimate represent what
market participants would use in pricing the liability component, including market interest rates,
credit standing, and yield curves, all of which are defined as Level 2 observable inputs. The
estimated implied interest rate was applied to the 2016 Notes, which resulted in a fair value of
the liability component of $748.5 million upon issuance, calculated as the present value of implied
future payments based on the $920.0 million aggregate principal amount. The $155.4 million
difference between the cash proceeds of $903.9 million and the estimated fair value of the
liability component was recorded in additional paid-in capital as the 2016 Notes are not considered
currently redeemable at the balance sheet date.
The interest expense recognized during the three and six months ended July 3, 2011 includes
$0.6 million and $0.7 million, respectively, for the contractual coupon interest, and $7.6 million
and $8.8 million, respectively, for the accretion of discount on the
liability component. If the 2016 Notes were converted as of July 3, 2011, the if-converted
value would not exceed the principal amount. As a policy election under applicable guidance related
to the calculation of diluted net income per share, the Company elected the combination settlement
method as its stated settlement policy and applied the treasury stock method in the calculation of
dilutive impact of the 2016 Notes, which was anti-dilutive for the three and six months ended July
3, 2011.
The Company used $314.3 million of the net proceeds to purchase 4,890,500 shares of its common
stock in privately negotiated transactions concurrently with the issuance. The Company also used
part of the net proceeds for the extinguishment of $87.8 million and $340.9 million principal
amount of its outstanding 0.625% convertible senior notes due 2014 upon conversions during the
three and six months ended July 3, 2011, respectively.
0.625% Convertible Senior Notes due 2014
On February 16, 2007, the Company issued $400.0 million principal amount of 0.625% convertible
senior notes due 2014 (the 2014 Notes). The Company pays 0.625% interest per annum on the principal
amount of the 2014 Notes, payable semi-annually in arrears in cash on February 15 and August 15 of
each year. The Company made an interest payment of $1.2 million on February 9, 2011. The 2014 Notes
mature on February 15, 2014. Additional information on the terms of the 2014 Notes was provided in
the 2010 annual report.
The Company entered into a hedge transaction concurrently with the issuance of the 2014 Notes
under which the Company is entitled to purchase up to 18,322,320 shares of the Company’s common
stock at a strike price of approximately $21.83 per share, subject to adjustment. In addition, the
Company sold to the hedge counterparties warrants exercisable, on a cashless basis, for up to
18,322,320 shares of the Company’s common stock at a strike price of $31.435 per share, subject to
adjustment.
The 2014 Notes became convertible into cash and shares of the Company’s common stock in
various prior periods and continue to be convertible through, and including, September 30, 2011.
During the three and six months ended July 3, 2011, the principal amount of any 2014 Notes
converted were repaid with cash and the excess of the conversion value over the principal amount
was paid in shares of common stock. The equity dilution resulted from the issuance of common stock
related to the conversion of the 2014 Notes was offset by repurchase of the same amount of shares
under the convertible note hedge transactions.
As a result of the conversions during the three and six months ended July 3, 2011, the Company
recorded losses on extinguishment of debt calculated as the difference between the estimated fair value of the debt and the
carrying value of the notes as of the settlement dates. To measure the fair value of the converted
notes as of the settlement dates, the applicable interest rates were estimated using Level 2
observable inputs and applied to the converted notes using the same methodology as in the issuance
date valuation.
The following table summarizes information about the conversions of the 2014 Notes during the
three and six months ended July 3, 2011(in thousands):
The following table summarizes information about the equity and liability components of the
2014 and 2016 Notes (in thousands). The fair values of the respective
notes outstanding were measured based on quoted market prices.
|
Share-based Compensation Expense (Details Textual) (USD $)
In Millions, unless otherwise specified |
6 Months Ended |
---|---|
Jul. 03, 2011
|
|
Share-based Compensation Expense [Abstract] | |
Unrecognized compensation cost related to stock options, restricted stock units and ESPP shares issued to date | $ 170.5 |
Weighted-average period of unrecognized compensation cost related to stock options, restricted stock units and ESPP shares issued to date | 2.4 |
M-F Q&R[]YUNZ??%\,=J!0(@WK(N!@(]2,3N!<3PQE/0I;!Q#">2G-R()IE
MBKV%%L"]YC^I13?-9!")@GBGC:([$\/ 8-FSUGPWM5I)PD;
M)3LPO2'^\@%;,%N*S^:8WG^(VEW/O2!4KJW`YF*0>KL*(.^M=\];;2<]\X-4
MY_#L)$4"$P,(2KE23'5M\BHX,/74D9HF`V8Q\UT:,9K4``6U2^F(1H&Y2_ZH
M1W^\N?'9#37XOWZ0>M4J<_C=C0?RZ7O6ONKQT/TH_2@]'GHOKF7 N>Y-/J;+&\Q:0P
MU%DK3KM.;FN5%!(1-SL*A@50":-X*7UPS:0C1NJQ*'99PK_;"P%HX.4J F=YW/`+N &H+!OX/>^Y7P`A^+'_["'8I\&\ZZ!MDXCVG,_M342+6):
M-[2X`MF=E8=];3D85E\&GY??M1$,3(.23:&_\[=_4A9L;J]`P__KIP^_O@=^
M==,P9I-QFJ8]@VX1R!7X*UM[?@A_OPJML*C._),%J6%S/Y4=\+WM,/\-3/.-
MYQ>4_$?8D)ER"3$&O$K7L=)'Y+%37\T.^07<%GO^WO$@?M@E\Z')93Z49/[;
MU=LM@1NCD3G2)Y-12N+2"-G!O[(;.T#43_BKM2JHQ1\^?OSMTX=?+Y4/O[Z1
MATE_*SO2[YZS<4/+Y\(H.(>_>O(`F4]D1_@#W([_@?W6O6)6`+O8XD,0;)A?
M2EMV?(L/:3LK]^?+^5\;FV.EQ#6\;V`<4"Q0,O@IL!>H#=A7<3[W-VSQT;:N
ML2^US8+=TZP#?9FEE9GF"P-F>6),8;W_Y\NJA#3-CK%M*7+8&0]G>O/L_&+9
M[CM^@>*O++W2KNP?_%H,NA6CR&)#LK7I6-M'=GK`LK31K1VMI6[7[&@!GB`"_&(WCR]4XD!MD.T]DT
M`ALQ`#8U!SR6T?0%^]L%)`2:_2HF[$S%//E;@RXT-*CI8.?:8!$YC43/FX>Y
M=35[:W84E9NH`HM:X]HN)$^546OYIWC!.NUQ]I+%/`7&-3,U?L'@`A%&$GWW
MH]5?4E^+2*^'ZG59WH8KLLH+>=/U6['L]L/H[,U.MK/+SO,8VDR9&K`2N%F!
M;G::RB20XTCH.PKS]B-[/D\*Q()#KJ7&P9V"B00QTIZQ*N<>=D0\'K_\O\[S
M]JU_78P$X\"]>,R3*?(O3W@>R@S,"=C%$%]#IU\:K$;(\?(`W!%PF$)PE.6VEPEP9M$NEX'1,"8)JGAP3BZ*2QD;`
M"07NR%4\C'=WB'85S@#0(K,)),8C>N7-61?7T/&RQ`$S"Y>35PV342C'8)`K
MUGZN>ZC&7`ZB3E8]#=FX,;D*2_,&9.-BT%L5235OE:@U]\Y<&J?==R>'9R?=
M7^8M*=US+6NM40Z6I5.TUPFEKC(Q.8:U_R9,*#EK6S0RABS.HPPKZC8>H%#'
M!*L%!+&7&/+-%IN(BQ*
M(F4)H!DAY6E9;B5J<\3-9;P%O=OXWEKX(9>!;5U\L;@S"6N?,,(?P4%PE4O0
M*IAP_MPG>[$`J_3."L($AG+E;6`972Z3QZ*91J,?I#=(D=<,DITRI;T0G7F;
M&ZP6#GC%J>='M@H\#/)W+6SI@$O,L9=@L-$HSY.`D:.?O2#*Q>9]4$WM#W'^
M.K*=O*L#>CD29?3=.3:Y$4%P)B^>O([A@3Q
541P%30G%T:()#$6'`=*YP<[44?)[!=](W\C6N78D3!
M#BG<,MH?
>)O@-]=GEH-4?/2"X(O'C>9'%@3?;BWWVSUS[H0YOKRY
M\=D-$(0/5O6%+L:CD22*Y@AMBSB^__;]ZOLO'EAC%W7Z^]4:G"(/C.7W=PB.
M6OMV@&89=HCO"5V'+3**4I_-GI8HWW@^1(/P?$EY&4]0];[!QX.-_W"TM#1=
M>Q+2*N9F7IBZ\:3$T:#=TL;CIR?*W>OPNWYHRWQ:TJIJY4